BioCentury | Jan 25, 2020
Tools & Techniques

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

...Staff Writer Deerfield Management Bio-Techne Corp. Fresenius SE & Co. KGaA Bellicum Pharmaceuticals Inc. University of Texas MD Anderson Cancer Center Nationwide Children's Hospital BridgeBio...
BioCentury | Aug 2, 2019
Clinical News

Amicus’ Batten disease gene therapy shows preserved speech, motor function

...in about 18 months. It gained rights to the CLN6 gene therapy when it acquired Nationwide Children's Hospital...
BioCentury | Apr 8, 2019
Company News

Audentes to develop vectorized antisense therapies with Nationwide

...Audentes partnered with Nationwide Children's Hospital to develop antisense oligonucleotides delivered with the biotech's adeno-associated viral (AAV) vectors...
...myotubular myopathy. Audentes was off $1.15 to $37.85 on Monday. Elizabeth S. Eaton, Staff Writer Audentes Therapeutics Inc. Nationwide Children's Hospital Muscular...
BioCentury | Mar 1, 2019
Company News

Sarepta acquires Myonexus, reports LGMD trial results

...the Myonexus programs share a rhesus monkey-derived vector, adeno-associated virus (AAV) rh.74, and inventors from Nationwide Children's Hospital...
BioCentury | Feb 27, 2019
Company News

On strength of first LGMD data, Sarepta exercises option to buy Myonexus

...the Myonexus programs share a rhesus monkey-derived vector, adeno-associated virus (AAV) rh.74, and inventors from Nationwide Children's Hospital...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

...Tuzman, Associate Editor American Society of Hematology Debiopharm Group Fate Therapeutics Inc. Genmab A/S Memorial Sloan Kettering Cancer Center Miltenyi Biotec GmbH Nationwide Children's Hospital Nordic...
BioCentury | Oct 5, 2018
Clinical News

Sarepta reports microdystrophin expression data for fourth patient in DMD gene therapy trial

...research-grade, third-party supplied plasmid. The company said at the time that preliminary testing from partner Nationwide Children's Hospital...
...to deliver a microdystrophin transgene designed to maintain spectrin-like repeats 2 and 3 (see "Sarepta, Nationwide Children's Hospital...
...gene expression by immunofluorescence and Western blot Status: Updated Phase I/IIa data Milestone: NA Jaime De Leon AAVrh74.MHCK7.micro-Dystrophin Nationwide Children's Hospital Sarepta...
BioCentury | Sep 28, 2018
Clinical News

FDA lifts holds on Epizyme, Sarepta programs

...research-grade, third-party supplied plasmid. The company said at the time that preliminary testing from partner Nationwide Children's Hospital...
BioCentury | Sep 24, 2018
Clinical News

FDA lifts holds on Epizyme, Sarepta programs

...research-grade, third-party supplied plasmid. The company said at the time that preliminary testing from partner Nationwide Children's Hospital...
BioCentury | Sep 21, 2018
Company News

Celenex takeout first of several expected Amicus gene therapy deals

...Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital...
...Inc. (NASDAQ:FOLD), Cranbury, N.J. Celenex, Columbus, Ohio Nationwide Children's Hospital, Columbus, Ohio Business: Gene therapy Allison Johnson Amicus Therapeutics Inc. Nationwide Children's Hospital Ohio...
Items per page:
1 - 10 of 52
BioCentury | Jan 25, 2020
Tools & Techniques

Manufacturing roundup: Deerfield launches new CDMO, plus a gene/cell therapy JV and more

...Staff Writer Deerfield Management Bio-Techne Corp. Fresenius SE & Co. KGaA Bellicum Pharmaceuticals Inc. University of Texas MD Anderson Cancer Center Nationwide Children's Hospital BridgeBio...
BioCentury | Aug 2, 2019
Clinical News

Amicus’ Batten disease gene therapy shows preserved speech, motor function

...in about 18 months. It gained rights to the CLN6 gene therapy when it acquired Nationwide Children's Hospital...
BioCentury | Apr 8, 2019
Company News

Audentes to develop vectorized antisense therapies with Nationwide

...Audentes partnered with Nationwide Children's Hospital to develop antisense oligonucleotides delivered with the biotech's adeno-associated viral (AAV) vectors...
...myotubular myopathy. Audentes was off $1.15 to $37.85 on Monday. Elizabeth S. Eaton, Staff Writer Audentes Therapeutics Inc. Nationwide Children's Hospital Muscular...
BioCentury | Mar 1, 2019
Company News

Sarepta acquires Myonexus, reports LGMD trial results

...the Myonexus programs share a rhesus monkey-derived vector, adeno-associated virus (AAV) rh.74, and inventors from Nationwide Children's Hospital...
BioCentury | Feb 27, 2019
Company News

On strength of first LGMD data, Sarepta exercises option to buy Myonexus

...the Myonexus programs share a rhesus monkey-derived vector, adeno-associated virus (AAV) rh.74, and inventors from Nationwide Children's Hospital...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

...Tuzman, Associate Editor American Society of Hematology Debiopharm Group Fate Therapeutics Inc. Genmab A/S Memorial Sloan Kettering Cancer Center Miltenyi Biotec GmbH Nationwide Children's Hospital Nordic...
BioCentury | Oct 5, 2018
Clinical News

Sarepta reports microdystrophin expression data for fourth patient in DMD gene therapy trial

...research-grade, third-party supplied plasmid. The company said at the time that preliminary testing from partner Nationwide Children's Hospital...
...to deliver a microdystrophin transgene designed to maintain spectrin-like repeats 2 and 3 (see "Sarepta, Nationwide Children's Hospital...
...gene expression by immunofluorescence and Western blot Status: Updated Phase I/IIa data Milestone: NA Jaime De Leon AAVrh74.MHCK7.micro-Dystrophin Nationwide Children's Hospital Sarepta...
BioCentury | Sep 28, 2018
Clinical News

FDA lifts holds on Epizyme, Sarepta programs

...research-grade, third-party supplied plasmid. The company said at the time that preliminary testing from partner Nationwide Children's Hospital...
BioCentury | Sep 24, 2018
Clinical News

FDA lifts holds on Epizyme, Sarepta programs

...research-grade, third-party supplied plasmid. The company said at the time that preliminary testing from partner Nationwide Children's Hospital...
BioCentury | Sep 21, 2018
Company News

Celenex takeout first of several expected Amicus gene therapy deals

...Inc. (NASDAQ:FOLD) has announced its entrance into the gene therapy space with the acquisition of Nationwide Children's Hospital...
...Inc. (NASDAQ:FOLD), Cranbury, N.J. Celenex, Columbus, Ohio Nationwide Children's Hospital, Columbus, Ohio Business: Gene therapy Allison Johnson Amicus Therapeutics Inc. Nationwide Children's Hospital Ohio...
Items per page:
1 - 10 of 52